Boehringer Ingelheim GmbH and partner Eli Lilly and Company’s Jardiance has won a European Commission thumbs up for the treatment of adults with chronic kidney disease (CKD), opening up a market that has previously been dominated by rival AstraZeneca PLC’s Farxiga.
BI/Lilly’s Jardiance To Face Off With AstraZeneca’s Farxiga In CKD After EU Nod
The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.
More from Genitourinary
• By
Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.
• By
Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.
• By
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
• By
The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.